|Place of Origin:||China|
|Brand Name:||Senwayer Brand|
|Certification:||ISO, 9001, USP|
|Minimum Order Quantity:||10grams|
|Price:||Discount is possible if your order is big enough|
|Packaging Details:||10g, 20g, 50g , 100g, 500g. 1kg, 10kg|
|Delivery Time:||within 2 working days|
|Payment Terms:||T/T in advance, Money Gram, Western Union, Bank Transfer.|
|Apparence:||Almost White Crystalline Powder||Purity:||99.5%|
|Usage:||Antithrombotic Drugs||Stock:||Enough Stock|
pharmaceutical raw chemical,
active pharmaceutical ingredients
99% Purity Rivaroxaban Intermediate 898543-06-1 Pharmaceutical Intermediates
Product Name: 4-[4-[(5S)-5-(Aminomethyl)-2-oxo-3-oxazolidinyl]phenyl]-3-morpholinone hydrochloride
Chemical name: 4-(4-((5s)-5-(aminomethyl)-2-oxo-3-oxazolidinyl)phenyl)-3-morpholinone hydrochloride; 4-(4-((5s)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl)phenyl)morpholin-3-one hydrochloride;
Molecular formula: C14H17N3O4・HCl
Molecular weight: 327.77
Appearance: white powder
Quality standard: ≥99%
CAS Registry Number: 898543-06-1
Packing: 1)Aluminum Foil Bag: 100g, 500g, 1Kg 2)Fiber Drum: 25Kg
Delivery Method: HKEMS, DHL, TNT, UPS, FEDEX, EMS, China Air Post etc.
Clearance Rate: 100% Custom Pass, Diguised Package and Safe Delivery
Delivery Time: 5-14 Working Days, Tracking Number Available
Payment Terms: T/T, MoneyGram, Western Union and Bitcoin
Origin: Hubei Province, China
Brand Name: Senwayer Brand
Production Capacity: 1000Kg/Month
Rivaroxaban and dabigatran etexilate are currently the most promising antithrombotic drugs, and compared to traditional antithrombotic drugs heparin, essential difference is that it does not require participation of antithrombin Ⅲ, directly antagonizes the free and bound Xa factor. And heparin needs to have antithrombin Ⅲ and can play a role, and is invalid to the prothrombin complex of Xa factor. Two new oral anticoagulants are praised as as a major step forward of anticoagulant therapy and potentially fatal thrombosis prevention in the medical field, will become a new milestone in the development of cardiovascular drugs.
Rivaroxaban is the world's first oral direct Xa factor inhibitor, can be high selectively, competitively inhibit free and bound Xa factor and activity of prothrombin, in a dose - dependent manner prolonged activated partial thromboplastin time board (PT) and prothrombin time (aPTT), thus prolonging the clotting time, reducing thrombin formation. Having characteristics of high bioavailability, a wide spectrum of disease treatment, dose effect relationship is stable, convenient oral administration, low bleeding risk.
Rivaroxaban also is drug for prevention and treatment of venous thrombosis. Clinically for the prevention of forming patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip joint and knee replacement surgery. It can also be used to prevent stroke and non-CNS systemic embolism in patients with non-valvular atrial fibrillation, reduce the risk of recurrent coronary syndrome, and so on.
Those who are allergic to the chemicals, pregnant women, severe infection, severe trauma patients before and after surgery and diabetic coma and insulin-dependent diabetes patients disabled.
1. severe liver and kidney dysfunction, should be reduced or caution.
2. ischemic heart disease, pituitary and adrenal insufficiency deputy, diarrhea, vomiting and malnutrition in patients with caution.
3. Elderly patients and children with caution.
4. Use the regular testing of blood glucose, while other hypoglycemic drugs such as insulin sensitizers, α- glucosidase inhibitors in combination to adjust the dosage.
|Doclatasvir Dihydrochloride||cas no.1009119-65-6|
|Ledipasvir Gs588||cas no.1256388-51-8|